Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
ARTV
ARTV
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ARTV News
Artiva Biotherapeutics Reports FY GAAP EPS of -$3.43
4h ago
seekingalpha
Artiva Biotherapeutics Appoints New CFO
Feb 24 2026
NASDAQ.COM
NanoSyrinx Appoints New CEO to Advance Nanosyringe Technology
Jan 08 2026
Newsfilter
Crude Oil Declines by More Than 1%; US Homebuilder Confidence Rises Slightly in December
Dec 15 2025
Benzinga
US Stocks Show Varied Performance as NY Manufacturing Activity Declines in December
Dec 15 2025
Benzinga
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Dec 09 2025
NASDAQ.COM
Artiva Biotherapeutics (ARTV) Soars 113.9% Following FDA Fast Track Designation for AlloNK in Refractory RA – Is the Bullish Outlook Still Valid?
Oct 19 2025
Yahoo Finance
Friday's Major Stock Market Highlights: Morning News Summary!
Oct 17 2025
TipRanks
What’s Behind the 105% Surge in Artiva Biotherapeutics Stock (ARTV) Today?
Oct 17 2025
TipRanks
Most Active Stocks in Pre-Market on October 17, 2025: BITF, SQQQ, ARTV, IONZ, TSLL, CREV, NIO, GWH, BBAI, IONQ, QBTS, LAC
Oct 17 2025
NASDAQ.COM
Needham Affirms Buy Rating for Artiva Biotherapeutics, Keeps $18 Price Target Intact
Oct 17 2025
Benzinga
Artiva (ARTV) Q2 Loss Widens 19.7%
Aug 07 2025
NASDAQ.COM
ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair
Jun 24 2025
Newsfilter
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
Apr 28 2025
Newsfilter
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
Apr 08 2025
Newsfilter
Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $23 Price Target
Apr 08 2025
Benzinga
Show More News
